Edition:
United States

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

157.32USD
17 Aug 2018
Change (% chg)

$0.19 (+0.12%)
Prev Close
$157.13
Open
$157.56
Day's High
$161.73
Day's Low
$156.93
Volume
46,720
Avg. Vol
106,031
52-wk High
$220.09
52-wk Low
$65.68

Chart for

About

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and... (more)

Overall

Beta: --
Market Cap(Mil.): $18,392.67
Shares Outstanding(Mil.): 63.55
Dividend: --
Yield (%): --

Financials

  BGNE.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -4.53 -- --
ROI: -25.99 2.89 12.63
ROE: -32.78 1.65 14.82

Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

Aug 02 2018

UPDATE 1-Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

* Deal is second under new rules for early-stage biotechs (Adds deal details, context)

Aug 02 2018

Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

HONG KONG, Aug 2 (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

Aug 02 2018

BRIEF-Beigene Initiates Phase 3 Trial Of Pamiparib As Maintenance Therapy In Chinese Patients With Ovarian Cancer

* BEIGENE INITIATES PHASE 3 TRIAL OF PAMIPARIB AS MAINTENANCE THERAPY IN CHINESE PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 17 2018

BRIEF-Beigene Reports Q1 Net Loss per ADS $2.03

* REVENUES FOR THREE MONTHS ENDED MARCH 31, 2018 WERE $32.54 MILLION, COMPARED TO NIL IN SAME PERIOD IN 2017

May 09 2018

BRIEF-BeiGene Says CEO John V. Oyler's 2017 Total Compensation Was $10.3 Million

* BEIGENE LTD SAYS CEO JOHN V. OYLER'S 2017 TOTAL COMPENSATION WAS $10.3 MILLION – SEC FILING Source : https://bit.ly/2r6wtIy Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 30 2018

BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting

* BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

Apr 16 2018

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MATURE T-AND NK-CELL LYMPHOMAS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 16 2018

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

Apr 10 2018

BRIEF-BeiGene Appoints J. Samuel Su To Its Board Of Directors

* BEIGENE APPOINTS J. SAMUEL SU TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Apr 03 2018

Earnings vs. Estimates